- Home
- YXT vs AIFF Comparison
YXT vs AIFF Comparison
Compare YXT & AIFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- AIFF
- Stock Information
- Founded
- YXT 2011
- AIFF 2006
- Country
- YXT China
- AIFF United States
- Employees
- YXT N/A
- AIFF N/A
- Industry
- YXT
- AIFF
- Sector
- YXT
- AIFF
- Exchange
- YXT NYSE
- AIFF NYSE
- Market Cap
- YXT 42.1M
- AIFF 41.5M
- IPO Year
- YXT 2024
- AIFF N/A
- Fundamental
- Price
- YXT $0.86
- AIFF $2.74
- Analyst Decision
- YXT
- AIFF
- Analyst Count
- YXT 0
- AIFF 0
- Target Price
- YXT N/A
- AIFF N/A
- AVG Volume (30 Days)
- YXT 18.8K
- AIFF 1.4M
- Earning Date
- YXT 06-24-2025
- AIFF 08-18-2025
- Dividend Yield
- YXT N/A
- AIFF N/A
- EPS Growth
- YXT N/A
- AIFF N/A
- EPS
- YXT N/A
- AIFF N/A
- Revenue
- YXT $45,374,087.00
- AIFF $139,000.00
- Revenue This Year
- YXT N/A
- AIFF N/A
- Revenue Next Year
- YXT N/A
- AIFF N/A
- P/E Ratio
- YXT $1.31
- AIFF N/A
- Revenue Growth
- YXT N/A
- AIFF N/A
- 52 Week Low
- YXT $0.47
- AIFF $1.86
- 52 Week High
- YXT $11.00
- AIFF $17.20
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- AIFF 36.25
- Support Level
- YXT N/A
- AIFF $3.03
- Resistance Level
- YXT N/A
- AIFF $3.21
- Average True Range (ATR)
- YXT 0.00
- AIFF 0.25
- MACD
- YXT 0.00
- AIFF -0.04
- Stochastic Oscillator
- YXT 0.00
- AIFF 3.74
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.